EU
EUZ.XETRA Eckert & Ziegler Strahlen- und Medizintechnik AG
- Market cap
- EUR 877M
- P/E
- 17.7x
- P/B
- 3.11x
- ROE
- 16.6%
- Dividend yield
- 1.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is EUZ.XETRA undervalued?
Graham numberEUZ.XETRA trades 56.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eckert & Ziegler Strahlen- und Medizintechnik AG fundamental analysis
No fundamental analysis for Eckert & Ziegler Strahlen- und Medizintechnik AG yet.
Eckert & Ziegler Strahlen- und Medizintechnik AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therap…
Full company profileEckert & Ziegler Strahlen- und Medizintechnik AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eckert & Ziegler Strahlen- und Medizintechnik AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 138M | 139M | 169M | 178M | 176M | 180M | 222M | 246M | 296M | 312M | 299M |
| Gross Profit | 66.1M | 63.9M | 74.3M | 87.0M | 86.5M | 91.1M | 107M | 116M | 143M | 147M | 145M |
| Operating Income | 15.2M | 19.2M | 23.2M | 31.6M | 35.2M | 46.0M | 47.0M | 47.0M | 61.1M | 75.1M | 69.0M |
| EBITDA | 25.3M | 26.9M | 32.0M | 43.4M | 43.1M | 56.7M | 57.9M | 59.7M | 85.4M | 92.1M | 85.0M |
| Net Income | 9.55M | 14.7M | 16.1M | 22.0M | 21.3M | 34.5M | 29.3M | 26.3M | 33.3M | 48.8M | 44.7M |
| EPS | 0.15 | 0.23 | 0.26 | 0.36 | 0.34 | 0.55 | 0.47 | 0.42 | 0.53 | 0.78 | 0.71 |
| Balance Sheet | |||||||||||
| Total Assets | 199M | 217M | 229M | 274M | 292M | 348M | 417M | 439M | 442M | 486M | 474M |
| Total Liabilities | 89.4M | 99.5M | 105M | 135M | 143M | 155M | 203M | 215M | 217M | 232M | 204M |
| Shareholders' Equity | 105M | 112M | 123M | 138M | 148M | 187M | 212M | 222M | 223M | 252M | 269M |
| Cash & Short-term Investments | 36.6M | 57.7M | 54.2M | 78.9M | 88.6M | 95.0M | 82.7M | 68.0M | 118M | 129M | 110M |
| Total Debt | 11.7M | 1.73M | 42.0K | 19.9M | 20.4M | 27.0M | 49.6M | 56.3M | 55.3M | 44.8M | 41.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 19.8M | 26.8M | 21.2M | 40.4M | 36.8M | 33.9M | 34.3M | 46.9M | 66.6M | 60.4M | 26.6M |
| Capital Expenditure | 5.33M | 4.16M | 6.12M | 7.25M | 8.91M | 28.9M | 31.1M | 26.3M | 17.2M | 26.0M | 19.7M |
| Free Cash Flow | 14.5M | 22.7M | 15.1M | 33.2M | 27.9M | 5.00M | 3.17M | 21.1M | 49.4M | 34.4M | 6.86M |
| Ratios | |||||||||||
| ROE | 9.1% | 13.1% | 13.2% | 15.9% | 14.4% | 18.4% | 13.8% | 11.8% | 14.9% | 19.4% | 16.6% |
| ROA | 4.8% | 6.8% | 7.0% | 8.0% | 7.3% | 9.9% | 7.0% | 6.0% | 7.5% | 10.0% | 9.4% |
| Net Profit Margin | 6.9% | 10.6% | 9.6% | 12.3% | 12.1% | 19.1% | 13.2% | 10.7% | 11.2% | 15.6% | 15.0% |
| Debt to Equity | 0.11x | 0.02x | 0.00x | 0.14x | 0.14x | 0.14x | 0.23x | 0.25x | 0.25x | 0.18x | 0.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eckert & Ziegler Strahlen- und Medizintechnik AG dividends
- Dividend yield
- 1.19%
- Forward dividend
- 0.22 EUR
- Payout ratio
- 21.4%
- Ex-dividend date
- Jun 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 10.4M | 0.17 | 21.4% |
| 2024 | EUR 1.04M | 0.02 | 3.1% |
| 2023 | EUR 10.4M | 0.17 | 39.6% |
| 2022 | EUR 10.4M | 0.17 | 35.5% |
| 2021 | EUR 9.32M | 0.15 | 27.0% |
| 2020 | EUR 8.75M | 0.14 | 41.1% |
| 2019 | EUR 6.18M | 0.10 | 28.1% |
| 2018 | EUR 4.13M | 0.07 | 25.6% |
| 2017 | EUR 3.49M | 0.05 | 23.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Aug 13, 2025.
Who owns Eckert & Ziegler Strahlen- und Medizintechnik AG
- Insiders 31.16%
- Institutions 24.23%
- Public & others 44.61%
- Shares outstanding 62.6M
- Free float 42.8M
Eckert & Ziegler Strahlen- und Medizintechnik AG company profile
- Company name
- Eckert & Ziegler Strahlen- und Medizintechnik AG
- Ticker
- EUZ.XETRA
- ISIN
- DE0005659700
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,105
- Fiscal year end
- December
- Address
- Robert-Rössle-Straße 10, Berlin, Germany, 13125
- Phone
- 49 30 94 10 84 0
- Website
- ezag.com
About Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services. It offers standard and radiation sources for medical and industrial sectors; medical imaging and spect diagnostics, industrial analytical and instrument, high activity CS-137 and CO-60, and oil well logging sources; blood irradiators and environmental disposal source services; and bulk isotopes as well as calibration-related sources for radioisotopes. In addition, the company offers Tc-99m generators and supplies, trade in raw isotopes and other products, and services. It serves medical, scientific, and industrial applications. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its name to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is headquartered in Berlin, Germany.
Eckert & Ziegler Strahlen- und Medizintechnik AG management
6- Dr. Harald HasselmannCEO & Chairman of the Executive Board of Medical Segment · born 1967
- Dr. Gunnar MannCOO & Member of the Executive Board · born 1967
- Ms. Karolin RiehleHead of Investor Relations & PR
- Mr. Joseph HathcockChief Operating Officer of Segment Isotope Products
- Ivan SimmerManaging Director of Eckert & Ziegler Cesio s.r.o.
- Mr. Julian SchröderHead of Group Controlling